Company: AEMD
Filing Date: 2025-02-12
Form Type: 10-Q
Source: 0001683168-25-000960
Chunk: 84

Company: AETHLON MEDICAL INC
Filing Date: 2025-02-12
Form: 10-Q
Item: Item 2
Chunk 84
---
 pre-funded warrants to purchase 5,650,000 shares
of common stock and accompanying Class A warrants to purchase up to 5,650,000 shares of common stock and Class B warrants to purchase
up to 5,650,000 shares of common stock, at a combined public offering price of $0.579 per pre-funded warrant and accompanying warrants,
which is equal to the public offering price per share of common stock and accompanying warrants, less the $0.001 per share exercise price
of each such pre-funded warrant. The gross proceeds from the offering, before deducting the placement agent’s fees and other offering
expenses, were approximately $4.7 million. Net proceeds, of the offering, after deducting the placement agent fees and expenses and other
offering expenses payable by us, were approximately $3.5 million. In June 2024, holders of Class A and Class B warrants exercised 300,000
shares and 2,880,000 shares, respectively, for additional total proceeds of $1,844,400. See the section entitled “May 2024 Public
Offering,” below, for additional information regarding this offering.

We do not expect our existing cash as of December
31, 2024 to be sufficient to fund our operations for at least twelve months from the issuance date of these financial statements. Significant
additional financing must be obtained to provide a sufficient source of operating capital and to allow us to continue to operate as a
going concern.  We intend to fund operations, working capital and other cash requirements for the twelve-month period subsequent
to December 31, 2024 through a combination of debt and/or equity financing arrangements and potentially from collaborations or strategic
partnerships.

As we expand our activities, our overhead costs
to support personnel, laboratory materials and infrastructure will increase and significant additional financing must be obtained to provide
a sufficient source of operating capital. Should the financing we require to sustain our working capital needs be unavailable to us on
reasonable terms, if at all, when we require it, we may be unable to support our research and our planned clinical trials. The failure
to implement our research and clinical trials would have a material adverse effect on our ability to conduct planned clinical trials and
commercialize our products.

Future capital requirements will depend upon many
factors, including progress with pre-clinical testing and clinical trials, the number and breadth of our clinical programs, the time and
costs involved in preparing, filing, prosecuting, maintaining and